The concomitant presence of NPM1/DNMT3A/FLT3-ITD mutations was observed in about 6% of AMLs, characterized by a high frequency of leukemia stem cells, an aberrant immunophenotype (with low CD34 expression, associated with high CD56 expression), and a high expression of hepatic leukemia factor (whose expression is required for the maintenance and the expansion of leukemic stem cells) [48]. The gene discussed is DNMT3A; the disease is leukemia.